Investigational Drugs for the Treatment of Acute Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Agents
BACKGROUND: Advances in our understanding of the complex pathophysiologic mechanisms responsible for high-risk atherosclerotic plaque rupture resulting in acute myocardial infarction (AMI) have led to the development of numerous antiplatelet and anticoagulant agents for treatment of AMI. Areas covered: We review various antithrombotic drugs which were recently investigated for the treatment of AMI. A MEDLINE search for relevant articles on newer antiplatelet agents and anticoagulants drugs for the treatment of AMI was performed, and important original investigations were reviewed. We also briefly discuss agents that completed evaluation and were recently recommended by expert guidelines. Expert opinion: The antiplatelet agents cangrelor and vorapaxar and the anticoagulant rivaroxaban, have shown promise for the reduction of ischemic events when administered during, and in the acute phase following AMI. However, these agents have not been compared with more potent P2Y12 inhibitors, prasugrel, and ticagrelor. Finding an optimum combination of these agents to achieve an appropriate risk (bleeding) - benefit (reduction in ischemic events) balance is challenging. Further evaluation of agents that show promise is important for enhancing our armamentarium of pharmacologic agents for the successful treatment of AMI.
Yandrapalli, S., Andries, G., Gupta, S., Dajani, A., & Aronow, W. (2019). Investigational Drugs for the Treatment of Acute Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Agents. Expert Opinion on Investigational Drugs, 28 (3), 223-234. https://doi.org/10.1080/13543784.2019.1559814